Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;27(3):210-6.
doi: 10.1097/ICU.0000000000000262.

Recent Advancements in Diabetic Retinopathy Treatment From the Diabetic Retinopathy Clinical Research Network

Affiliations
Free PMC article
Review

Recent Advancements in Diabetic Retinopathy Treatment From the Diabetic Retinopathy Clinical Research Network

Carl W Baker et al. Curr Opin Ophthalmol. .
Free PMC article

Abstract

Purpose of review: Diabetic retinopathy and diabetic macular edema (DME) are common eye diseases leading to vision loss. The Diabetic Retinopathy Clinical Research Network (DRCRnet), a collaboration of private and academic practices supported by the National Eye Institute and the National Institute of Diabetes, Digestive and Kidney Diseases has studied diabetic eye disease for 13 years. This review will discuss the network's findings over the last year, when some of its most important contributions were reported.

Recent findings: The DRCRnet reported intravitreal bevacizumab, ranibizumab and aflibercept all improve visual acuity in DME. With baseline vision of 20/30 to 20/40, all agents had similar efficacy. With baseline vision of 20/50 or worse, aflibercept resulted in superior visual improvement. Protocol S, which compared panretinal photocoagulation with intravitreal injections of ranibizumab for proliferative diabetic retinopathy (PDR), found vision outcomes and surgery rates were not inferior in the injection group. Secondary outcomes indicate improved functional results with ranibizumab supporting injections as a possible alternative treatment for PDR.

Summary: The DRCRnet has helped clarify the role of various treatments for both DME and PDR, and will continue to evaluate treatments for these vision-threatening conditions.

Conflict of interest statement

Conflicts of interest

Dr. Baker performs clinical research for Genentech, Regeneron, Alcon, Ophthotech, Iconic, Allergan, Thrombogenics, Acucela, Alimera, GlaxoSmithKline, National Institutes of Health. He has served on an advisory board for Roche.

Dr. Stone performs clinical research for Genentech, Regeneron and owns stock in Regeneron.

Figures

Figure 1
Figure 1
Mean Change in Visual Acuity over Time, A) Overall, B) Stratified by baseline visual acuity (approximate Snellen equivalent): 20/50 or worse (solid lines) and 20/32–20/40 (dashed lines). Change in visual acuity was truncated to 3 standard deviations from the mean. Published with permission [15]
Figure 2
Figure 2
Visual Acuity Results from Protocol S. [14]

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles
Feedback